Before revealing that the tumor exhibited an NRASQ61 mutation (Table S2 and Figure S3A), the drug screen suggested MAPK pathway engagement and cellular sensitivity to MEK inhibitors (Figure 2A). This evidence concerns the gene MAP2K7 and neoplasm.